- Home
- FC vs DRUG Comparison
FC vs DRUG Comparison
Compare FC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FC
- DRUG
- Stock Information
- Founded
- FC 1983
- DRUG 2019
- Country
- FC United States
- DRUG United States
- Employees
- FC N/A
- DRUG N/A
- Industry
- FC Other Consumer Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- FC Consumer Discretionary
- DRUG Health Care
- Exchange
- FC Nasdaq
- DRUG Nasdaq
- Market Cap
- FC 279.6M
- DRUG 233.2M
- IPO Year
- FC 1992
- DRUG N/A
- Fundamental
- Price
- FC $23.20
- DRUG $32.61
- Analyst Decision
- FC Strong Buy
- DRUG Strong Buy
- Analyst Count
- FC 2
- DRUG 6
- Target Price
- FC $42.50
- DRUG $83.25
- AVG Volume (30 Days)
- FC 84.5K
- DRUG 28.8K
- Earning Date
- FC 06-25-2025
- DRUG 05-27-2025
- Dividend Yield
- FC N/A
- DRUG N/A
- EPS Growth
- FC 8.95
- DRUG N/A
- EPS
- FC 1.34
- DRUG N/A
- Revenue
- FC $286,195,000.00
- DRUG N/A
- Revenue This Year
- FC N/A
- DRUG N/A
- Revenue Next Year
- FC $5.25
- DRUG N/A
- P/E Ratio
- FC $17.38
- DRUG N/A
- Revenue Growth
- FC 2.53
- DRUG N/A
- 52 Week Low
- FC $18.94
- DRUG $0.93
- 52 Week High
- FC $44.46
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- FC 57.43
- DRUG 51.70
- Support Level
- FC $20.10
- DRUG $30.81
- Resistance Level
- FC $21.79
- DRUG $32.75
- Average True Range (ATR)
- FC 0.69
- DRUG 2.41
- MACD
- FC 0.59
- DRUG 0.25
- Stochastic Oscillator
- FC 88.20
- DRUG 47.85
About FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.